Loading…
← CockpitCompetitor Analysis › 688351.SS Shanghai MicroPort EP Medtech Co., Ltd. Class AOpen in the cockpit ↗

Shanghai MicroPort EP Medtech Co., Ltd. Class A688351.SSCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services

Chinese maker of cardiac electrophysiology medical devices, including ablation catheters, part of the MicroPort medical-device group.

≈ A China-based Biosense Webster/Abbott EP peerMomentum strong 69
Mkt cap
$1.31B
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$11.4M
20-day average traded
Fwd P/E
137.1×
forward earnings
ROIC−WACC
+0.3 pp
WACC 5.0%
Hurdle
+16 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · CNYCN¥18.48
1D-2.6%
1W+3.0%
1M+7.4%
3M-11.0%
6M-29.9%
YTD-20.2%
1Y-25.0%
ATR %4.2%
52w lowhigh34.6% off high

What Shanghai MicroPort EP Medtech does

Chinese maker of cardiac electrophysiology medical devices, including ablation catheters, part of the MicroPort medical-device group.

Places mapping systems in hospitals and earns on the single-use catheters used in each ablation procedure, so every system installed brings repeat catheter sales. Hospital buying of such devices in China is increasingly steered by group purchasing programmes, which push prices down.

In one line: A China-based Biosense Webster/Abbott EP peer.

Products and services

  • Ablation catheters
  • EP diagnostic/mapping systems

Customers

  • Hospitals/cardiologists

Where it sits in the supply chain

  • Medical devices
  • Cardiac electrophysiology
  • Ablation catheters and EP systems

What could go right

  • Growing cardiac ablation procedure volumes in China

What could go wrong

  • Competition from global EP device makers
  • Procedure reimbursement policy

Moat: narrow (IP / patents, regulatory licence, customer qualification). Regulatory approval and physician training create switching costs for EP devices.

Headquarters: Shanghai, China · Employees: 523

Shanghai MicroPort EP Medtech at a glance

Size Shanghai MicroPort EP Medtech (688351.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.31B, the 1727th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.48 on 18 Nov 2026.

Performance Over six months the shares fell 29.9%, against -15.3% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 19.8% over the last twelve months (peer median +4.9%); the operating margin is 2.5% (peer median 8.5%).

Valuation It trades at 137.1× forward earnings against a peer median of 23.3× (2nd most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 42% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 85688351.SS 70
Six months, rebased to 100: Shanghai MicroPort EP Medtech against the median of its 20 peers (local-currency closes).

Shanghai MicroPort EP Medtech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥549MCN¥462MCN¥410MCN¥327MCN¥259M
Revenue growth—+12%+25%+26%—
Gross profitCN¥310MCN¥236MCN¥206MCN¥181MCN¥162M
EBITDAn/aCN¥60.3MCN¥46.0M-CN¥5.14MCN¥1.60M
Net incomeCN¥57.4MCN¥51.1MCN¥52.1MCN¥5.69MCN¥3.07M
Free cash flowCN¥39.7M-CN¥13.5MCN¥48.5M-CN¥54.7M-CN¥37.1M
Capital expenditureCN¥52.2MCN¥122MCN¥43.8MCN¥41.9MCN¥31.9M
Total debtCN¥74.2MCN¥34.7MCN¥29.7MCN¥26.1MCN¥27.7M

Quarterly statements and history in the cockpit →

Shanghai MicroPort EP Medtech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%97460023386006546881282384CRAI688800300725CONCORDBIODBGCLVTCMPDI688202301413002607ICFIAFRY603406600662688112688351.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai MicroPort EP Medtech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×97460023386881282384688800300725DBGCLVT688202301413002607ICFI600662688112688351.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai MicroPort EP Medtech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%-25%0%25%50%97466006546881282384CRAI688800300725CONCORDBIODBGCLVT002607688112688351.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai MicroPort EP Medtech is the large dot.

Shanghai MicroPort EP Medtech competitors and peer comparison

How Shanghai MicroPort EP Medtech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai MicroPort EP Medtech against its 20 peers (data as of 18 Nov 2026)
Measure688351.SSPeer medianRank in peer set
1-month return+7.4%-5.9%5th highest of 21
6-month return-29.9%-15.3%5th lowest of 21
Distance from 52-week high-34.6%-37.8%10th highest of 21
Revenue growth (TTM)+19.8%+4.9%4th highest of 21
Operating margin2.5%8.5%6th lowest of 21
Forward P/E137.1×23.3×2nd most expensive of 18
Growth the price implies (Req g, 7 yrs)42.5%6.6%3rd most demanding of 17
Growth delivered (Del g)+26.7%+11.1%2nd highest of 17
Hurdle (Req g minus delivered)+15.7 pp-3.0 pp4th most demanding of 17
ROIC minus cost of capital+0.3 pp+0.6 pp10th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai MicroPort EP Medtech 688351.SSChina$1.31B-30%+20%3%137.1×42.5%+26.7%
TKC 9746.TJapan$1.31B+22%+5%20%19.1×-10.1%+5.7%
Changchun Up Optotech 002338.SZChina$1.34B-41%+22%2%43.1×n/an/a
China Security 600654.SSChina$1.34B-31%-30%-1%n/a56.0%+0.4%
China National Electric Apparatus Research Institute 688128.SSChina$1.35B-17%+8%11%14.7×3.2%+13.5%
SBS 2384.TJapan$1.35B+26%+17%5%13.9×-4.7%+13.8%
CRA International CRAIUnited States$1.35B+46%+13%10%23.3×6.6%+8.1%
Suzhou Recodeal Interconnect System 688800.SSChina$1.26B-68%+5%9%31.0×22.7%+38.9%
PharmaBlock Sciences (Nanjing) 300725.SZChina$1.36B+5%+11%11%37.5×24.2%+14.1%
Concord Biotech CONCORDBIO.NSIndia$1.26B-2%+4%28%33.9×44.4%+11.6%
Derichebourg DBG.PAFrance$1.37B-18%-3%5%8.8×6.7%+6.3%
Clarivate CLVTUnited States$1.38B-12%-9%8%3.5×13.2%+14.4%
Central Mine Planning & Design Institute CMPDI.NSIndia$1.38B-22%+10%33%n/a4.5%+18.7%
Shanghai Medicilon 688202.SSChina$1.39B+8%+42%-2%85.1×n/an/a
Shenzhen Ampron Technology 301413.SZChina$1.40B-28%+11%2%387.2×n/an/a
Offcn Education Technology 002607.SZChina$1.40B-40%-2%13%34.7×15.7%-27.6%
ICF International ICFIUnited States$1.40B+14%-5%8%10.4×-2.5%+4.4%
AFRY AFRY.STSweden$1.42B+5%-4%7%12.5×-2.2%+6.3%
Yangzhou Tinfulong 603406.SSChina$1.42B-29%-4%12%n/a6.1%+10.6%
Shanghai Foreign Service 600662.SSChina$1.42B-14%+1%2%13.2×n/an/a
Siglent Technologies 688112.SSChina$1.19B-26%+30%24%39.2×27.7%+22.0%

Questions

Which companies are Shanghai MicroPort EP Medtech's closest peers?
The cockpit's peer set: TKC (9746.T), Changchun Up Optotech (002338.SZ), China Security (600654.SS), China National Electric Apparatus Research Institute (688128.SS), SBS (2384.T), CRA International (CRAI), Suzhou Recodeal Interconnect System (688800.SS), PharmaBlock Sciences (Nanjing) (300725.SZ).
Is Shanghai MicroPort EP Medtech expensive compared with its peers?
On forward p/e it trades at 137.1× against a peer median of 23.3×, 2nd most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 42% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shanghai MicroPort EP Medtech stock performed?
Over six months to 18 Nov 2026 the shares returned -29.9% against -15.3% for the median peer; over one year -25.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.